In 2026, the FDA is stepping up oversight around compounding practices and marketing claims, particularly for peptides commonly used off-label (like BPC-157 and TB-500)
Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis
Specifically, we solicited feedback on alternative approaches to encourage specialty reporting of relevant MVPs, the appropriate data sources, volume threshold, and determination period to assign clinicians to an MVP, and clinician readiness to report an MVP assigned according to Medicare Part B claims data
Peripheral arterial disease and critical limb ischemia represent potential applications based on BPC-157's pro-angiogenic effects and demonstrated improvements in blood flow recovery in hind limb ischemia models
It feels right, doesn't it